---
title: "Ionis Q2 FY26 revenue drops 40.71% to $268 million; operating loss widens to $102 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294196819.md"
description: "Ionis Pharmaceuticals reported a 40.71% drop in Q2 FY26 revenue to $268 million, with an operating loss widening to $102 million. GAAP net loss was $115 million, compared to net income of $124 million last year. While commercial revenue rose 15% to $119 million, R&D revenue fell significantly due to the absence of a prior-year upfront payment. The company maintains its 2026 guidance and holds $2.1 billion in cash."
datetime: "2026-07-29T11:07:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294196819.md)
  - [en](https://longbridge.com/en/news/294196819.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294196819.md)
generator: "portal-rs"
---

# Ionis Q2 FY26 revenue drops 40.71% to $268 million; operating loss widens to $102 million

-   Ionis posted Q2 GAAP revenue of $268 million, down 40.71% year over year; operating loss widened to $102 million from operating income of $140 million. \* GAAP net loss was $115 million, swinging from net income of $124 million; diluted loss per share was $0.69 versus earnings per share of $0.70. \* Commercial revenue rose 15% to $119 million, while R&D revenue fell 57.31% to $149 million, excluding a prior-year one-time sapablursen upfront payment. \* TRYNGOLZA generated net product sales of $5 million, DAWNZERA delivered $26 million; cash and short-term investments were $2.1 billion at June 30. \* Management cited early TRYNGOLZA sHTG launch momentum, expects Alexander disease decision for zilganersen by Sept. 22, 2026, and reiterated it is on track for 2026 guidance. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief on July 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [IONS.US](https://longbridge.com/en/quote/IONS.US.md)

## Related News & Research

- [Great Lakes Advisors LLC Acquires Shares of 66,924 Ionis Pharmaceuticals, Inc. $IONS](https://longbridge.com/en/news/296455358.md)
- [How TRYNGOLZA Approval and New Equity Shelf At Ionis Pharmaceuticals (IONS) Has Changed Its Investment Story](https://longbridge.com/en/news/295401431.md)
- [Baker Hughes declares Q3 2026 dividend of R$ 0.81 per unit](https://longbridge.com/en/news/296392545.md)
- [Northrop Grumman announces R$ 0.17 per unit dividend for Q3 2026](https://longbridge.com/en/news/296645808.md)
- [Corning sets Q3 2026 dividend at R$ 0.25 per unit](https://longbridge.com/en/news/296635714.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**